津巴布韦镰状细胞病患者疼痛管理的药物遗传学。
Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease.
机构信息
Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), 911 Boronia Township, Beatrice, Zimbabwe.
Department of Biotechnology, Chinhoyi University of Technology, Private Bag 7724, Chinhoyi, Zimbabwe.
出版信息
Pharmacogenomics. 2023 May;24(7):359-369. doi: 10.2217/pgs-2023-0045. Epub 2023 May 30.
Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. The authors conducted a cross-sectional study to determine the effect of and polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm pharmacogenomics open array panel containing and genetic variants implicated in opioid response. The reduced function alleles and had high frequencies of 15.9% and 12.9%, respectively. rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454). This study demonstrated the role of polymorphism in SCD patient pain management.
疼痛是镰状细胞病（SCD）患者住院的常见原因。未能有效控制疼痛仍然是患者护理面临的挑战。作者进行了一项横断面研究，以确定 和 多态性对 106 名津巴布韦 SCD 患者疼痛管理的影响。参与者信息通过问卷收集。基因分型使用包含与阿片类药物反应相关的 和 遗传变异的 GenoPharm 药物基因组学开放式阵列面板进行。功能降低等位基因 和 的频率分别为 15.9%和 12.9%。rs73823859 与疼痛水平呈显著统计学相关性（p=0.0454）。本研究表明 多态性在 SCD 患者疼痛管理中的作用。
Zotero 插件